<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336982</url>
  </required_header>
  <id_info>
    <org_study_id>CC-90009-AML-002</org_study_id>
    <secondary_id>U1111-1247-5619</secondary_id>
    <secondary_id>2019-001681-15</secondary_id>
    <nct_id>NCT04336982</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia</brief_title>
  <official_title>An Exploratory Phase 1/2 Open-Label Multi-Arm Trial to Evaluate the Safety and Efficacy of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CC-90009-AML-002 is an exploratory Phase 1b open-label multi-arm trial to evaluate the safety&#xD;
      and efficacy of CC-90009 in combination with anti-leukemia agents in subjects with acute&#xD;
      myeloid leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study CC-90009-AML-002 is an open-label, multi-arm, parallel multi-cohort, multicenter, Phase&#xD;
      1b study to determine the safety, tolerability, PK, and efficacy of CC 90009 in combination&#xD;
      with anti-leukemia agents used for the treatment of AML. CC 90009 will be given as a&#xD;
      combination therapy to subjects with newly diagnosed (ND) or relapsed or refractory (R/R)&#xD;
      AML.&#xD;
&#xD;
      The dose and schedule finding part (Part A) of the study will evaluate the safety, PK and PD&#xD;
      data, and preliminary efficacy information and determine the Part B dose and schedule for&#xD;
      each arm.&#xD;
&#xD;
      The expansion part (Part B) of the study will further evaluate the safety and efficacy of the&#xD;
      CC-90009 containing combination at or below the maximum tolerated dose (MTD) in the selected&#xD;
      cohorts in order to determine the recommended Phase 2 dose (RP2D) for subjects with AML.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Adverse change in the risk/benefit&#xD;
  </why_stopped>
  <start_date type="Actual">August 5, 2020</start_date>
  <completion_date type="Anticipated">October 17, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of participants with a DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 28 days.</time_frame>
    <description>The highest dose with DLT rate in Cycle 1 being lower than or close to the target level 0.3 and the toxicity probability within (0.25, 0.35) interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 28 days after last dose of study drug.</time_frame>
    <description>An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Remission Rate (CRR),</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>is defined as the rate for any type of CR or CRh</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>is defined as the rate for all types of CRs and PR for AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>is defined as the time from the first dose of study drug(s) to the first occurrence of relapse or progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>is measured as the time from the first dose of study drug(s) to death due to any cause and will be analyzed in a manner similar to that described for PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Remission</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>is measured from the time when criteria for CR/CRh/PR are first met (whichever is first recorded) until the first date at which relapse, or progressive disease is objectively documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Remission</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>is measured from the time when criteria for CR/CRh/PR are first met (whichever is first recorded)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Until last CC-90009 dose in Cycle 3 (each cycle is 28 days. CC-90009 dosing days are Days 1-5 in Cycle 3)</time_frame>
    <description>observed maximum concentration in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC24</measure>
    <time_frame>Until last CC-90009 dose in Cycle 3 (each cycle is 28 days. CC-90009 dosing days are Days 1-5 in Cycle 3)</time_frame>
    <description>area under the plasma concentration time-curve from time 0 to 24 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - t1/2</measure>
    <time_frame>Until last CC-90009 dose in Cycle 3 (each cycle is 28 days. CC-90009 dosing days are Days 1-5 in Cycle 3)</time_frame>
    <description>terminal half life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>CC-90009 in combination with venetoclax and azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Venetoclax will be administered orally QD.&#xD;
Azacitidine will be administered intravenously or subcutaneously on planned dosing days for each cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90009 in combination with gilteritinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Gilteritinib will be administered orally QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90009</intervention_name>
    <description>Injection</description>
    <arm_group_label>CC-90009 in combination with venetoclax and azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Tablet</description>
    <arm_group_label>CC-90009 in combination with venetoclax and azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Injection</description>
    <arm_group_label>CC-90009 in combination with venetoclax and azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gilteritinib</intervention_name>
    <description>Tablet</description>
    <arm_group_label>CC-90009 in combination with gilteritinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult subject must understand and voluntarily sign an ICF prior to any study-related&#xD;
             assessments/procedures being conducted.&#xD;
&#xD;
          2. Arm A (CC-90009 + venetoclax/azacitidine):&#xD;
&#xD;
               1. Newly diagnosed AML and is ≥ 75 years of age or intensive chemotherapy ineligible&#xD;
                  OR&#xD;
&#xD;
               2. Refractory AML and is ≥ 18 years of age&#xD;
&#xD;
          3. Arm B (CC-90009 + gilteritinib):&#xD;
&#xD;
               1. Subject is ≥ 18 years of age.&#xD;
&#xD;
               2. FLT3-ITD positive relapsed or refractory AML.&#xD;
&#xD;
               3. Gilteritinib treatment naïve&#xD;
&#xD;
          4. Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.&#xD;
&#xD;
          5. Subject must have the following screening laboratory values:&#xD;
&#xD;
               -  Total White Blood Cell count (WBC) &lt; 25 x 10^9 prior to study treatments.&#xD;
                  Treatment with hydroxyurea to achieve this level is allowed.&#xD;
&#xD;
               -  Selected electrolytes within normal limits or correctable with supplements.&#xD;
&#xD;
                    -  Participant must have adequate liver function as demonstrated by: Aspartate&#xD;
                       aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper&#xD;
                       limit of normal (ULN) and bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
                    -  Participant has adequate renal function as demonstrated by an estimated&#xD;
                       serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault&#xD;
                       equation.&#xD;
&#xD;
          6. Agree to follow the CC-90009 Pregnancy Prevention Plan (PPP) and combination agents'&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with acute promyelocytic leukemia (APL)&#xD;
&#xD;
          2. Subject has received systemic anticancer therapy (including investigational therapy)&#xD;
             or radiotherapy &lt; 28 days or 5 half-lives, whichever is shorter, prior to the start of&#xD;
             study treatment&#xD;
&#xD;
          3. Patients with prior autologous hematopoietic stem cell transplant (HSCT) who, in the&#xD;
             investigator's judgment, have not fully recovered from the effects of the last&#xD;
             transplant (eg, transplant related side effects)&#xD;
&#xD;
          4. Prior allogeneic HSCT with either standard or reduced intensity conditioning ≤ 6&#xD;
             months prior to dosing&#xD;
&#xD;
          5. Subject on systemic immunosuppressive therapy post HSCT at the time of screening, or&#xD;
             with clinically significant graft-versus-host disease (GVHD). The use of topical&#xD;
             steroids for ongoing skin or ocular GVHD is permitted&#xD;
&#xD;
          6. Subject has persistent, clinically significant non-hematologic toxicities from prior&#xD;
             therapies which have not recovered to &lt; Grade 2&#xD;
&#xD;
          7. Subject has or is suspected of having central nervous system (CNS) leukemia.&#xD;
             Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is&#xD;
             suspected during screening.&#xD;
&#xD;
          8. Disorders or conditions disrupting normal calcium homeostasis or preventing calcium&#xD;
             supplementation.&#xD;
&#xD;
          9. Impaired cardiac function or clinically significant cardiac diseases, including any of&#xD;
             the following:&#xD;
&#xD;
               1. Left ventricular ejection fraction (LVEF) &lt; 45% as determined by multiple gated&#xD;
                  acquisition (MUGA) scan or echocardiogram (ECHO).&#xD;
&#xD;
               2. Complete left bundle branch or bifascicular block.&#xD;
&#xD;
               3. Congenital long QT syndrome.&#xD;
&#xD;
               4. Persistent or clinically meaningful ventricular arrhythmias.&#xD;
&#xD;
               5. QTcF ≥ 470 ms (Arm A) or &gt; 450 ms (Arm B) on Screening electrocardiogram (ECG)&#xD;
&#xD;
               6. Unstable angina pectoris or myocardial infarction ≤ 6 months prior to starting&#xD;
                  study treatments or unstable arrhythmia.&#xD;
&#xD;
               7. Cardiovascular disability status of New York Heart Association Class ≥2. Class 2&#xD;
                  is defined as cardiac disease in which patients are comfortable at rest but&#xD;
                  ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal&#xD;
                  pain.&#xD;
&#xD;
         10. Subject is a pregnant or lactating female&#xD;
&#xD;
         11. Additional exclusion criteria based on combination agent:&#xD;
&#xD;
             a. For Combination Arm A (venetoclax/azacitidine):&#xD;
&#xD;
               -  Received strong or moderate CYP3A inhibitors or inducers or P-gp inhibitors&#xD;
                  within 7 days prior to initiation of first venetoclax dose.&#xD;
&#xD;
               -  Subject has consumed grapefruit, grapefruit products, Seville oranges (including&#xD;
                  marmalade containing Seville oranges), or Star fruit within 3 days prior to first&#xD;
                  venetoclax dose through last dose of venetoclax.&#xD;
&#xD;
         12. Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20&#xD;
             days for severe/critical illness prior to C1D1.&#xD;
&#xD;
             a. Acute symptoms must have resolved and based on investigator assessment in&#xD;
             consultation with the medical monitor, there are no sequelae that would place the&#xD;
             participant at a higher risk of receiving study treatment.&#xD;
&#xD;
         13. Previous SARS-CoV-2 vaccine within 14 days of C1D1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Pourdehnad, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Mass General Brigham Cancer Care, Inc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-90009</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>Gilteritinib</keyword>
  <keyword>Hematologic cancers</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:&#xD;
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

